HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy

Sandeep Arora, Roberta Catania, Amir Borhani, Natally Horvat, Kathryn Fowler, Carla Harmath*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Liver cancer is the fastest-growing cause of cancer deaths in the United States and is a complex disease. The response of hepatocellular carcinoma (HCC) to treatment can be variable. Predicting response to determine the most effective therapy is an active area of research. Our understanding of underlying factors which drive response to therapy is continually increasing. As more therapies for the treatment of this disease evolve, it is crucial to identify and match the ideal therapy for a particular tumor and patient. The potential predicative imaging features of tumor behavior, while of research interest, have not been validated for clinical use and do not currently inform treatment planning. If further validated though, prognostic features may be used in the future to personalize treatment plans according to individual patients and tumors. Unexpected post-treatment responses such as potential tumor biology changes and abscopal effect which are important to be aware of. This review is intended for radiologists who routinely interpret post treatment HCC imaging and is designed to increase their cognizance about how HCC tumor biology drives response to therapy and explore rare responses to therapy.

Original languageEnglish (US)
Pages (from-to)3686-3697
Number of pages12
JournalAbdominal Radiology
Volume46
Issue number8
DOIs
StatePublished - Aug 2021

Keywords

  • HCC
  • Hepatocellular carcinoma
  • Treatment response
  • Tumor biology

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Fingerprint

Dive into the research topics of 'HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy'. Together they form a unique fingerprint.

Cite this